Clinical trial RGX-202-002
A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer
| Organ | Multiple |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Inspirna |
| EudraCT Identifier | 2023-503356-27-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05983367 |
| Last update |